These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9218207)

  • 1. Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection?
    Ferrari R
    J Hypertens Suppl; 1997 Mar; 15(2):S109-17. PubMed ID: 9218207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of calcium antagonists in ischaemic heart disease.
    Pepine CJ
    Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-ischemic potential of drugs related to the renin-angiotensin system.
    Ertl G; Hu K
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of myocardial ischemia therapy: calcium antagonists and ACE-inhibitors].
    Ferrari R
    Cardiologia; 1994 Dec; 39(12 Suppl 1):203-6. PubMed ID: 7634268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands.
    Morisco C; Lembo G; Sarno D; Argenziano L; Fratta L; Rozza F; Trimarco B
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S27-33. PubMed ID: 9605599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment.
    Muller CA; Opie LH; Pineda CA; McCarthy J; Kraljevic V
    Cardiovasc Drugs Ther; 1998 Oct; 12(5):449-55. PubMed ID: 9926275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction.
    Poole-Wilson PA
    Am J Cardiol; 1995 Apr; 75(13):4E-9E. PubMed ID: 7726123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
    Remme WJ
    Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.
    Juggi JS; Koenig-Berard E; Van Gilst WH
    Can J Cardiol; 1993 May; 9(4):336-52. PubMed ID: 8513428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sympathetic nervous system and ischaemic heart disease.
    Remme WJ
    Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE-inhibitors in coronary artery disease?
    Vogt M; Motz W; Strauer BE
    Basic Res Cardiol; 1993; 88 Suppl 1():43-64. PubMed ID: 8357335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart.
    Kawabata H; Ryomoto T; Ishikawa K
    Jpn Circ J; 2000 Apr; 64(4):276-82. PubMed ID: 10783050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.